Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

July 31, 2008 09:01 ET

Ambrilia: Second Quarter 2008 Results Conference Call and Webcast

MONTREAL, QUEBEC--(Marketwire - July 31, 2008) - Ambrilia Biopharma Inc. (TSX:AMB) today announced that it will be hosting a conference call and webcast on Monday, August 11, 2008, at 9:00 am ET, to discuss the financial results for its second quarter ended June 30, 2008, and the recent developments. Prior to the conference call, a press release will be issued on Friday, August 8, after market close. The call will be hosted by Dr. Philippe Calais, President and Chief Executive Officer, and Ms. Monique Letourneau, Executive Vice-President, Finance and Chief Financial Officer.

Interested parties may access the conference call by way of telephone or webcast. The numbers to access the conference call are 416 644 3417 (international) and 1 800 731 5319 (toll free). The webcast will be available on the Company's website at, Investors' section, Conference calls and webcasts, and will be archived for 365 days.

A replay of the call will be available on the Company's website at, Investors' section, Conference calls and webcasts, from Monday, August 11, 2008, 11:00 am ET to Monday, August 18, 2008, 11:59 pm ET, and the numbers to access the replay are 416 640 1917 (international) and 1 877 289 8525 (toll free) with access code 21278770.


Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, an HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.) as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.

Contact Information